Syros Pharmaceuticals, Inc. (SYRS)
Sector: Biotechnology
Industry: Biotechnology
Syros Pharmaceuticals, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 2,244 |
| Nov 13, 2026 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 2,299 |
| Nov 12, 2026 | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 10,994 |
| Nov 11, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 3,142 |
| Nov 10, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 516 |
| Nov 9, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 3,092 |
| Nov 6, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 27,171 |
| Nov 5, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 7,527 |
| Nov 4, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 1,055 |
| Nov 3, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 999 |
| Nov 2, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 8,588 |
| Oct 30, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 1,947 |
| Oct 29, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 5,825 |
| Oct 28, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 11,447 |
| Oct 27, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 4,782 |
| Oct 26, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 1,498 |
| Oct 22, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 202 |
| Oct 21, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 803 |
| Oct 20, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 30,546 |
| Oct 19, 2026 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 3,024 |
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Director | Sale | 37.1K | $10.0K | Dec 2, 2024 | |
| Director | Sale | 134.7K | $35.7K | Nov 25, 2024 | |
| Chief Legal & Compliance Offic | Sale | 46.7K | $10.3K | Nov 19, 2024 | |
| Chief Development Officer | Sale | 36.1K | $7.9K | Nov 18, 2024 | |
| President & CEO | Sale | 134.8K | $26.9K | Nov 18, 2024 | |
| Chief Financial Officer | Sale | 137.8K | $29.0K | Nov 18, 2024 |
| Name | Shares | % | Source |
|---|---|---|---|
Bain Capital Life Sciences Fund II, L.P. 2 · may incl. warrants· stale · filed Nov 2024 | 2.8M | 10.0% | 13G |
Avidity Partners Management LP · filed Feb 2025 | 2.0M | 7.6% | 13G |
Invus Public Equities, L.P. · filed Feb 2025 | 0+1.1M via warrants | 3.8% | 13G |
Samsara BioCapital, L.P. · filed Mar 2025 | 0+707.1K via warrants | 2.6% | 13D |
Ally Bridge MedAlpha Master Fund L.P. · may incl. warrants· stale · filed Feb 2024 | 571.0K | 2.6% | 13G |
Adage Capital Management, L.P. · filed Feb 2025 | 531.9K | 2.0% | 13G |
Blue Owl Capital Holdings LP · filed Nov 2024 | 515.9K | 1.9% | 13G |
Young Richard A Director | 10.7K | -- | FORM 4 |
AKKARAJU SRINIVAS Director | 9.3K | -- | FORM 4 |
Simonian Nancy A Director | 4.0K | -- | FORM 4 |
Insiders
- Simonian Nancy ADirector
- Quirk Gerald EChief Legal & Compliance Offic
- Stephens KristinChief Development Officer
- Chee ConleyPresident & CEO
- Haas JasonChief Financial Officer
- Roth DavidChief Medical Officer
- Young Richard ADirector
- AKKARAJU SRINIVASDirector
Syros Pharmaceuticals, Inc. operates as a biopharmaceutical firm primarily focused on discovering and developing novel therapeutic solutions for various cancers and monogenic (single-gene) diseases. A key strategic aim for the company involves cultivating a robust pipeline of medicines that modulate gene expression.
Its leading investigational drug candidates include: Tamibarotene: A selective retinoic acid receptor alpha agonist, currently undergoing Phase III clinical trials for a genetically defined subset of patients with myelodysplastic syndrome, and in Phase II trials for individuals suffering from acute myeloid leukemia. SY-2101: An innovative oral formulation of arsenic trioxide, intended for the treatment of acute promyelocytic leukemia. SY-5609: A cyclin-dependent kinase 7 inhibitor, which is being assessed in a Phase I clinical study involving patients with specific advanced solid tumors. Syros maintains several strategic alliances, notably a research collaboration and option agreement with Incyte Corporation centered on identifying therapeutic targets for myeloproliferative neoplasms. Furthermore, the company has a licensing arrangement with TMRC Co. Ltd. pertaining to the development and commercialization of tamibarotene. Initially incorporated in 2011 as LS22, Inc., the company officially adopted the name Syros Pharmaceuticals, Inc. in August 2012.
Its corporate headquarters are located in Cambridge, Massachusetts.
No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.
30d Avg
6.38K
60d Avg
13.27K
90d Avg
13.82K
Syros Pharmaceuticals, Inc. (OTC: SYRS) traded at $0.0001 on Nov 16, 2026. 52-week range: $0.0000 to $0.0200. The company is in the Healthcare sector (Biotechnology).